Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGF-Endoret eye drops for stage 2-3 neurotrophic keratitis
2015-003326-13Phase 4Active
- Sponsor
- BTI Biotechnology Institute
- Start
- Nov 2015
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of PRGF-Endoret in neurotrophic keratitis (NK) (2 arms), sponsored by BTI Biotechnology Institute. Primary endpoint: Reduction of corneal ulcer/keratitis area at 4 weeks. Started Nov 2015; status: active.
02
Drugs
PRGF-Endoret
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on 2015-003326-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003326-13.